BenzingaSeptember 2, 2026 at 2:32 AM NY2 days ago

Morgan Stanley Reinstates Overweight on Vertex Pharmaceuticals, Announces $665 Price Target

Morgan Stanley analyst Terence Flynn reinstates Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and announces $665 price target.

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga

Companies in This Story